Barclays
KROS icon

Barclays’s Keros Therapeutics KROS Stock Holding History

Barclays’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,100
Closed -$124K – 5260
2025
Q4 		$124K Buy
+6,100
New +$107K ﹤0.01% 4518

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Barclays's KROS Position: Q2 2026 in Review

Barclays increased its Keros Therapeutics (KROS) stake by 115% in Q2 2026, buying an estimated $296K and bringing the position to 49,704 shares worth $532K. The position accounts for ﹤0.01% of the portfolio, ranked #3180.

Barclays first reported a position in KROS in Q1 2022 and has held it in 18 quarters since. The position peaked at $10.3M in Q4 2023. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Barclays held 49,704 shares of Keros Therapeutics worth $532K as of Q2 2026.
  • Barclays bought 26,547 Keros Therapeutics shares in Q2 2026, an estimated $296K.
  • Keros Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3180 holding.
  • Barclays first reported a position in Keros Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Keros Therapeutics position peaked at $10.3M in Q4 2023.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.